A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

China

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality

Zhejiang Cancer Hospital, Hangzhou, Zhejiang